Xenon Pharmaceuticals Inc
XENE32.610USD
+2.110+6.92%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
2.50BCap. mercado
PérdidaP/E TTM
Más Datos de Xenon Pharmaceuticals Inc Compañía
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, the Company's lead Kv7 channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. Azetukalner is being developed for the treatment of epilepsy, including focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS) as well as major depressive disorder (MDD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications. It has an ongoing collaboration with Neurocrine Biosciences, Inc. to develop treatments for epilepsy.
Información de la empresa
Símbolo de cotizaciónXENE
Nombre de la empresaXenon Pharmaceuticals Inc
Fecha de salida a bolsaOct 17, 2014
Director ejecutivoMr. Ian C. Mortimer, CPA
Número de empleados316
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 17
Dirección3650 Gilmore Way
CiudadVANCOUVER
Bolsa de valoresNASDAQ Global Market Consolidated
PaísCanada
Código postalV5G 4W8
Teléfono16044843300
Sitio Webhttps://www.xenon-pharma.com/
Símbolo de cotizaciónXENE
Fecha de salida a bolsaOct 17, 2014
Director ejecutivoMr. Ian C. Mortimer, CPA
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ian C. Mortimer, CPA
Mr. Ian C. Mortimer, CPA
President, Chief Executive Officer, Interim Chief Financial Officer, Director
President, Chief Executive Officer, Interim Chief Financial Officer, Director
45.60K
--
Dr. Gary Patou, M.D.
Dr. Gary Patou, M.D.
Independent Director
Independent Director
28.48K
--
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
25.00K
--
Mr. Steven R. (Steve) Gannon, CPA
Mr. Steven R. (Steve) Gannon, CPA
Independent Director
Independent Director
7.14K
-0.04%
Dr. Christopher Kenney, M.D.
Dr. Christopher Kenney, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Darren S. Cline
Mr. Darren S. Cline
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Patrick Machado, J.D.
Mr. Patrick Machado, J.D.
Independent Director
Independent Director
--
--
Dr. Gillian M. Cannon, Ph.D.
Dr. Gillian M. Cannon, Ph.D.
Independent Director
Independent Director
--
--
Mr. Justin Gover
Mr. Justin Gover
Independent Director
Independent Director
--
--
Ms. Andrea Marie Difabio, J.D.
Ms. Andrea Marie Difabio, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ian C. Mortimer, CPA
Mr. Ian C. Mortimer, CPA
President, Chief Executive Officer, Interim Chief Financial Officer, Director
President, Chief Executive Officer, Interim Chief Financial Officer, Director
45.60K
--
Dr. Gary Patou, M.D.
Dr. Gary Patou, M.D.
Independent Director
Independent Director
28.48K
--
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
25.00K
--
Mr. Steven R. (Steve) Gannon, CPA
Mr. Steven R. (Steve) Gannon, CPA
Independent Director
Independent Director
7.14K
-0.04%
Dr. Christopher Kenney, M.D.
Dr. Christopher Kenney, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Darren S. Cline
Mr. Darren S. Cline
Chief Commercial Officer
Chief Commercial Officer
--
--
Desglose de ingresos
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
Canada
7.50M
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: dom., 3 de ago
Actualizado: dom., 3 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
8.03%
Avoro Capital Advisors LLC
7.48%
Driehaus Capital Management, LLC
5.97%
Wellington Management Company, LLP
4.94%
Janus Henderson Investors
4.33%
Other
69.25%
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
8.03%
Avoro Capital Advisors LLC
7.48%
Driehaus Capital Management, LLC
5.97%
Wellington Management Company, LLP
4.94%
Janus Henderson Investors
4.33%
Other
69.25%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
46.54%
Investment Advisor
30.34%
Hedge Fund
23.10%
Private Equity
1.66%
Venture Capital
1.05%
Sovereign Wealth Fund
0.83%
Research Firm
0.77%
Pension Fund
0.56%
Bank and Trust
0.27%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
416
84.68M
110.35%
+9.65K
2025Q1
434
79.94M
104.19%
-5.23M
2024Q4
434
79.81M
104.31%
-4.80M
2024Q3
425
77.49M
102.39%
-3.82M
2024Q2
431
76.92M
102.03%
-4.12M
2024Q1
421
76.68M
101.81%
-2.76M
2023Q4
404
75.13M
102.42%
+7.65M
2023Q3
386
64.60M
99.41%
-3.93M
2023Q2
377
64.25M
101.09%
-4.03M
2023Q1
347
63.79M
101.12%
-4.16M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Fidelity Management & Research Company LLC
6.16M
8.03%
+73.87K
+1.21%
Mar 31, 2025
Avoro Capital Advisors LLC
5.74M
7.48%
+75.00K
+1.32%
Mar 31, 2025
Driehaus Capital Management, LLC
4.58M
5.97%
+64.26K
+1.42%
Mar 31, 2025
Wellington Management Company, LLP
3.79M
4.94%
+11.59K
+0.31%
Mar 31, 2025
Janus Henderson Investors
3.33M
4.33%
+458.34K
+15.99%
Mar 31, 2025
Capital International Investors
3.09M
4.03%
+541.52K
+21.26%
Mar 31, 2025
Braidwell LP
2.71M
3.53%
-204.09K
-7.00%
Mar 31, 2025
Polar Capital LLP
2.62M
3.42%
-74.62K
-2.77%
Mar 31, 2025
Commodore Capital LP
2.33M
3.03%
-415.00K
-15.15%
Mar 31, 2025
Capital World Investors
2.22M
2.9%
-69.82K
-3.04%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Neuroscience and Healthcare ETF
4.34%
Tema Neuroscience and Mental Health ETF
1.82%
ALPS Medical Breakthroughs ETF
1.62%
Virtus LifeSci Biotech Clinical Trials ETF
0.86%
Goldman Sachs Future Health Care Equity ETF
0.61%
First Trust Multi-Manager Small Cap Opportunities ETF
0.52%
Harbor Health Care ETF
0.42%
BNY Mellon Innovators ETF
0.35%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.34%
iShares Health Innovation Active ETF
0.34%
Ver más
iShares Neuroscience and Healthcare ETF
Proporción4.34%
Tema Neuroscience and Mental Health ETF
Proporción1.82%
ALPS Medical Breakthroughs ETF
Proporción1.62%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.86%
Goldman Sachs Future Health Care Equity ETF
Proporción0.61%
First Trust Multi-Manager Small Cap Opportunities ETF
Proporción0.52%
Harbor Health Care ETF
Proporción0.42%
BNY Mellon Innovators ETF
Proporción0.35%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proporción0.34%
iShares Health Innovation Active ETF
Proporción0.34%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
